Organs-On-Chips Market: Current Analysis and Forecast (2021-2027)

An organ-on-chip refers to a microfluidic cell culture device with continuously perfused chambers. This chip creates a narrow channel for blood and airflow in organs like the lung, heart, liver, intestine, and others. These devices generate multiple levels of tissue and organ functionality that are not possible with traditional 2D and 3D culture systems. It has numerous applications, including patient stratification, disease modelling, and phenotypic screening. Moreover, rising need for alternatives to animal testing, increasing demand for early detection of drug toxicity, as well as new product launches and technological advancements are the crucial factors propelling the market growth. For instance, in December 2020, CN Bio and the University of Melbourne collaborated to develop therapies through the lung-on-a-chip technology for respiratory complications among patients who have recovered from COVID-19. Furthermore, the mounting demand for personalized medication and wide-range applications of organ-on-chip beyond the pharmaceutical industry are the crucial factors providing lucrative opportunities for market growth.

Based on organ type, the Organs-On-Chips Market is segmented into Heart, Liver, Lung, and Others. Among these, the heart segment is expected to exhibit higher potential for the market growth owing to the rising incidences of cardiovascular diseases. However, Lung segment dominated the global organ-on-chip market and is maintain its dominance during the forecast period.

Based on application, the market is bifurcated into Drug Discovery, Toxicology Research, Physiological Model Development, Others. With the increasing costs associated with the development of new drugs, rising competition, and availability of limited time to peak sales, the importance of getting a drug launch right is becoming greater. Hence, the need for organ-on-chip for drug discovery is increasing dramatically in the market.

Based on end-user, the market is divided into Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others. Of these segments, pharmaceutical and biotechnology companies are projected to experience highest CAGR during the forecast period owing to the increasing demand for organ-on-chip device for drug discovery purpose.

For a better understanding of the market, the report is analyzed based on different regions including North America (US, Canada, Rest of North America); Europe (Germany, UK, France, Italy, Rest of Europe); Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of Asia-Pacific); and Rest of World. North America accounts for the largest share of the market and is also projected to witness highest CAGR followed by Europe. The biggest share of the region attributes to the factors like the convenient government initiatives in terms of funding and programs for basic drug development and research, availability of advanced organs-on-chips models in the market, and strong presence of essential pharmaceutical companies.

Some of the major players operating in the market include MIMETAS BV, SynVivo Inc., Emulate Inc., InSphero AG, CN Bio, Nortis Inc., Organovo Holdings Inc., TissUse GmbH, AxoSim Inc., Kirkstall Ltd.